Thematic Intelligence - Biosimilars in oncology
Summary
Clients will gain insight into the percentage of cancer patients treated with biosimilars, the price of these agents compared to their originator, and key opinion leaders’ outlook for the products. The report includes the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars. Additionally, the report includes the opportunities and challenges facing biosimilar uptake and a commercial assessment of the major players in the field. The report is supplemented with insight from four key opinion leaders, one payer, and 103 high-prescribing physicians surveyed in the 8MM.
The biosimilar market has increased sharply in the last five years, and GlobalData projects moderately high future growth at a compound annual growth rate (CAGR) of 9.1%
Europe leads the way for oncology biosimilars in the 8MM. China is at the forefront in the emerging markets
Pricing is a key issue for biosimilars entering an increasingly crowded market
Sandoz and Amgen are main players in the development of biosimilars in oncology
Key Highlights
Report deliverables include a PowerPoint report
Survey & Clinical trial analysis includes 8 countries
4 KOLs and one payer interviewed
Scope
Contents include -
- Biosimilars in oncology overview
- Trends
- Value chain
- Leading marketed and pipeline products
- Market analysis
- Regulatory landscape and market access
- Opportunities and unmet needs
- Commercial assessment - major current and future players in the biosimilar field
OBTAIN Biosimilars in oncology MARKET ASSESSMENT ACROSS MULTIPLE REGIONS
GAIN INSIGHT INTO APPROACHES REQUIRED TO PROMOTE BIOSIMILAR UPTAKE
Our thematic reports answer questions such as -
- What is the percentage of cancer patients treated with biosimilars in each 8MM country?
- Which patient groups are more likely to receive these therapies?
- What is the price of these agents compared to their originator molecule?
- What is the key opinion leaders’ outlook for the products?
- How do biosimilar discounts work and how might they affect future uptake?
- Executive Summary
- Biosimilars in Oncology Overview
- Biosimilars Overview
- What Are Biosimilars According to Regulators
- Most Important Milestones of Biosimilars in Oncology in the 8MM
- Biosimilar Value Chain
- Generics Versus Biosimilars
- Biosimilarity Versus Interchangeability
- Drug Rebates Affecting Biosimilar Uptake in the US
- Biosimilars in Oncology Trends
- Biosimilar Pricing
- Biosimilar Market Share
- Oncology Biosimilar Uptake in the US
- Oncology Biosimilar Uptake in the 5EU
- Oncology Biosimilar Uptake in Japan
- Oncology Biosimilar Uptake in China
- Biosimilars in Oncology Clinical Trials
- Market Analysis
- Market Analysis and Forecast of Biosimilars in Oncology
- US Biosimilar Market Potential
- 5EU Biosimilar Market Potential
- Japan Biosimilar Market Potential
- China Biosimilar Market Potential
- Marketed Products
- Biosimilars Approved
- Biosimilars Approved - Important Indications for Oncology Biosimilars
- Total Market Size for Marketed Biosimilars in Oncology
- Leading Trastuzumab Biosimilar Brands
- Leading Bevacizumab Biosimilar Brands
- Leading Rituximab Biosimilar Brands
- Leading Biosimilars for Supportive Care
- Pipeline Products
- Biosimilars in Oncology Pipeline Products in the 8MM
- Reference Biologics for Future Biosimilars
- Upcoming Biosimilars for Marketed Products: Curative Care
- Upcoming Biosimilars for Marketed Products: Supportive Care
- Future Biosimilars in Oncology
- Regulatory
- Innovator Biologic Versus Biosimilar Development Programs
- Totality of Evidence Approach Used to Review Biosimilar Applications
- Stepwise Approach Used in Biosimilar Development
- Biosimilar Regulatory Pathway in the 8MM
- US Biosimilar Regulatory Pathway
- Data Required for Regulatory Approval Ex-US
- Differences Between the Biosimilar Regulatory Pathways in the 8MM
- Opportunities, Challenges, and Unmet Needs
- Potential for Biosimilars of Immune Checkpoint Inhibitors
- Physician Preference for Biosimilar Versus Subcutaneous Formulation
- Physician Hesitancy to Prescribe Biosimilars
- Physician Perspective on Automatic Substitution and Extrapolation
- Factors that Influence Biosimilar Prescription
- Desired Discounts for Biosimilars in Oncology
- Expected Changes in Prescription Patterns
- Initiatives to Encourage Future Use of Biosimilars
- Unmet Needs Biosimilars in Oncology - Gap Analysis
- Companies
- Current Major Players - Sandoz
- Current Major Players - Celltrion
- Current Major Players - Amgen
- Current Major Players - Biocon
- Current Major Players - Pfizer
- Current Major Players - Organon
- Appendix
- Sources
- Primary Research
- Key Themes Impacting the Pharmaceutical Industry
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook